Over the last thirteen years, bioRxiv and medRxiv have grown into widely used infrastructure for rapid research sharing in biology and medicine. The reliability and researcher-first values that have defined these platforms since their founding remain central to how we operate, and building on the trust, partnerships, and community relationships researchers worldwide depend on is…
Homepage - openRxiv
openRxiv is an independent non-profit, the new organizational home for bioRxiv and medRxiv, enabling researchers to instantly share groundbreaking findings with the global scientific community.
Introducing Hypothesis commenting on bioRxiv and medRxiv: an updated way to engage with preprints - openRxiv
An important part of our mission at openRxiv is to collaborate with other organizations to improve science communication and promote interoperability. Preprints are just one part of the research workflow, and we want to ensure they are effectively integrated with the tools and communities that drive scientific progress. Today, we’re excited to share about another…
The Story behind the Science: Preprints of pandemic potential—how bioRxiv and medRxiv brought preprints to the life sciences
ABSTRACT The bioRxiv and medRxiv preprint servers brought preprinting to the life sciences and played a critical role in disseminating COVID research during the pandemic. Here, I reflect on the birth of bioRxiv and medRxiv and the crucial role so many members of the community played, our experience during the pandemic, and the launch of the new non-profit organization set up to oversee the servers. The pandemic was a stress test for bioRxiv and medRxiv that demonstrated their value and robustness. Under the umbrella of openRxiv, they are now poised to become long-term infrastructure underpinning a new publishing ecosystem.
A new automated feedback option for authors - openRxiv
Authors who post preprints on openRxiv servers can get formal and informal feedback on their manuscripts in a number of ways. Our bioRxiv to journal (B2J) and medRxiv to journal (M2J) pipelines are linked to traditional peer review venues, enabling authors to save time by submitting directly from bioRxiv or medRxiv to any one of…
Frontiers in Open Science
Curvenote Reader brings a better reading experience to half a million openRxiv preprints
Curvenote Reader is now live across half a million bioRxiv preprints - bringing inline citations, zoomable figures, and connected context directly into the reading flow. Find out how we modernized one of science's biggest preprint repositories without disrupting a single workflow.
Open Social Network Cookbook
The Open Social Network Cookbook is the collective product of the Open Social Incubator, a cohort that MEDLab hosted from Fall 2024 to Spring 2025. At the heart of our work together was the question: How can the online communities that we participate in use tools that truly reflect our values?
OpenRxiv & Curvenote’s new Reader launch took to the stage at FORCE11 2026
At FORCE11 2026, Curvenote showcased the newly launched Curvenote Reader deployed over all of openRxiv to enthusiastic feedback from scientific publishing leaders — with callouts on the innovation from the opening and closing keynotes as a meaningful step forward for open science.
Center for Open Science
At the Center for Open Science, our mission is to increase openness, integrity, and reproducibility of scholarly research. Promoting these practices within the research funding and publishing communities accelerates scientific progress
A Research Lab for Open Source ✸ Software Stewardship Lab
Today, we're launching a world-class research lab dedicated to Open Source sustainability with a team of some of the most experienced people in the world.
eLife Pathways home page
Moving beyond legacy publishing requires interoperable open-source infrastructure. With Wellcome’s support, we are evolving eLife’s technology to anchor a collaborative network, partnering with the open science community to reshape the communication and assessment of global research.
Life sciences verification program
Starting today, teams and institutions can apply to our Life Sciences Verification Program (LSVP), which gives verified researchers and organizations access to our most capable models for professional biology and drug development work. LSVP is built for teams of all kinds: academic labs, startups, non-profits, biotechs, pharma companies, and more. Learn more and apply here: https://lnkd.in/gDjrMm7D We know that it has been frustrating to encounter blocks on Claude Fable. LSVP is our mechanism to prevent biological misuse, like the documented cases we’ve disrupted, while enabling legitimate life sciences research. LSVP includes a new set of safeguards to provide a better UX for life sciences researchers. We believe that advancing biology research and drug discovery will realize some of the most important beneficial impacts of AI. Please DM me if you run into any issues with the application. https://lnkd.in/gNQYePZp | 35 comments on LinkedIn
Empowering science communities with open, democratic, researcher-owned infrastructure.
We’re building communities and tech for publishing, curating, sharing, and discussing research online using ATProto and other decentralized protocols.
Empowering science communities with open, democratic, researcher-owned infrastructure.
We’re building communities and tech for publishing, curating, sharing, and discussing research online using ATProto and other decentralized protocols.
Meet Rosalind Workbench: Empowering every scientist to be their own research team | OpenAI Developers
How guided tasks, scientific viewers, and sequencing analysis help researchers follow a question from data to evidence.
We live in a golden age of biology. So why are people still dying from disease? Because discovery and development move slower than they should. Today, we’re partnering with Incyte to change… | Samuel G. Rodriques | 491 comments
We live in a golden age of biology. So why are people still dying from disease? Because discovery and development move slower than they should. Today, we’re partnering with Incyte to change that. Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. Incyte will be the first company to deploy it across their pipeline. Work that used to take a team of scientists months now happens in weeks. Patients can't wait, and neither can we. | 491 comments on LinkedIn